Loading…
Ocular Therapeutix, Inc. is projected to rise to $9.69 by 2027, a +14% move from its current price of $8.54. OCUL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $8.29 | $8.54 | $8.79 | 0.00% |
| May 30 | $8.20 | $8.54 | $8.90 | +0.01% |
| May 31 | $8.12 | $8.54 | $8.98 | +0.01% |
| Jun 1 | $8.06 | $8.54 | $9.05 | +0.01% |
| Jun 2 | $8.00 | $8.54 | $9.12 | +0.01% |
| Jun 3 | $7.95 | $8.54 | $9.17 | +0.02% |
| Jun 4 | $7.91 | $8.54 | $9.23 | +0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.91 | $8.54 | $9.23 | +0.02% |
| Week 2 | $7.66 | $8.54 | $9.53 | +0.04% |
| Week 3 | $7.48 | $8.55 | $9.77 | +0.06% |
| Week 4 | $7.33 | $8.55 | $9.97 | +0.08% |
| Week 5 | $7.19 | $8.55 | $10.16 | +0.10% |
| Week 6 | $7.08 | $8.55 | $10.33 | +0.12% |
| Week 7 | $6.97 | $8.55 | $10.49 | +0.14% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ocular Therapeutix, Inc. is a healthcare company that engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. It markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
The company is developing AXPAXLI, an axitinib intravitreal hydrogel in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. It has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc.
was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
OCUL is a healthcare stock with a current price of $8.23 and a market cap of $1.8B. It is ranked 2071. The stock trades in the Healthcare sector and carries a set of near-term and multi-year forecasts.
Technically, the current price sits below key moving averages, suggesting near-term softness relative to trend lines. The forecast shows a neutral near-term view for 2026 with a rising long-term trajectory through 2030, 2040, and 2050, culminating in substantially higher average prices by 2050. This path implies meaningful upside potential over the coming years, conditional on market conditions and company-specific developments.
A major floor 19.4% below — a decisive break under it would weaken the trend.
The nearest floor, 6.4% below — buyers have tended to step in here.
The nearest ceiling, 15.0% above — a clean break opens room to run.
A major ceiling 34.1% above — clearing it would confirm fresh momentum.
Key OCUL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OCUL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.26 | Buy | $8.39 | Buy |
| MA 10 | $8.56 | Sell | $8.55 | Sell |
| MA 20 | $9.03 | Sell | $8.80 | Sell |
| MA 50 | $8.83 | Sell | $9.04 | Sell |
| MA 100 | $9.33 | Sell | $9.49 | Sell |
| MA 200 | $10.80 | Sell | $9.87 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.97 | Neutral |
| Stoch RSI (14) | 45.08 | Neutral |
| CCI (20) | -58.96 | Neutral |
| Williams %R (14) | -67.46 | Info |
| MACD (12,26,9) | -0.11 | Sell |
| ROC (12) | -11.50 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 32.54 | Neutral |
| TRIX (15) | -0.17 | Sell |
| Awesome (5,34) | -0.86 | Sell |
| Ultimate (7,14,28) | 33.65 | Neutral |
| Momentum (10) | -0.62 | Sell |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 8.23 | Buy |
| ADX (14) | 16.21 | Neutral |
| ATR (14) | 0.21 | Info |
The 30-day technical picture is bearish, with RSI(14) at 40. The price is below the 50-day simple moving average of $8.84 and the 200-day simple moving average of $10.84, indicating current weakness relative to intermediate and long-term trend lines. Near-term support is identified at $7.99 and resistance at $9.82, framing a cautious trading range in the low-to-mid single digits.
The 30-day range spans from a low of $6.74 to a high of $10.05, highlighting recent volatility. Annualized volatility is 60%, underscoring a high level of price fluctuation over the period. Overall, the near-term picture is constrained, with a bearish tilt in sentiment persisting into the immediate horizon.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.88 | $8.54 | $11.19 | 0% | Neutral | |
| $7.64 | $9.69 | $13.06 | +14% | Neutral | |
| $7.28 | $9.51 | $13.31 | +11% | Neutral | |
| $7.39 | $9.90 | $14.27 | +16% | Neutral | |
| $9.18 | $12.56 | $18.57 | +47% | Bullish | |
| $9.98 | $13.94 | $21.06 | +63% | Bullish | |
| $10.54 | $15.00 | $23.12 | +76% | Bullish | |
| $11.40 | $16.50 | $25.90 | +93% | Bullish | |
| $10.75 | $15.83 | $25.25 | +85% | Bullish | |
| $11.16 | $16.70 | $27.05 | +96% | Bullish | |
| $14.90 | $23.96 | $41.39 | +181% | Bullish | |
| $28.27 | $51.63 | $97.92 | +505% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $6.88 | $8.54 | $10.06 | +0.00% |
| June 2026 | $7.41 | $8.71 | $10.50 | +2.02% |
| July 2026 | $7.21 | $8.56 | $10.47 | -1.72% |
| August 2026 | $7.05 | $8.42 | $10.41 | -1.64% |
| September 2026 | $7.22 | $8.68 | $10.83 | +3.10% |
| October 2026 | $7.35 | $8.88 | $11.17 | +2.30% |
| November 2026 | $7.20 | $8.74 | $11.07 | -1.57% |
| December 2026 | $7.20 | $8.78 | $11.19 | +0.44% |
Click any year to see its month-by-month OCUL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, OCUL could reach as high as $11.19, with a base case around $8.54 and support toward $6.88 — roughly 0% from $8.54. Price action looks broadly range-bound.
Expect OCUL to range from $7.64 to $13.06 through 2027. The $9.69 average target implies a +14% move from current prices. That is up +14% on the projected 2026 average. A consolidation phase looks the most probable path here.
The OCUL price prediction for 2028 points to an average of $9.51 (low $7.28, high $13.31) — a potential gain of +11% on today's $8.54. Price action looks broadly range-bound.
In 2029, OCUL is projected to trade between $7.39 and $14.27, averaging $9.90 — a potential gain of +16% from today's $8.54. That is up +4% on the projected 2028 average. A consolidation phase looks the most probable path here.
Ocular Therapeutix, Inc.'s 2030 outlook centres on $12.56, within a $9.18 to $18.57 range. That is up +27% on the projected 2029 average. That marks a +47% change versus current levels. Momentum favours further upside here.
By 2031, OCUL could reach as high as $21.06, with a base case around $13.94 and support toward $9.98 — roughly +63% from $8.54. Buyers look set to stay in control over this stretch.
Expect OCUL to range from $10.54 to $23.12 through 2032. The $15.00 average target implies a +76% move from current prices. That is up +8% on the projected 2031 average. Momentum favours further upside here.
The OCUL price prediction for 2033 points to an average of $16.50 (low $11.40, high $25.90) — a potential gain of +93% on today's $8.54. Buyers look set to stay in control over this stretch.
In 2034, OCUL is projected to trade between $10.75 and $25.25, averaging $15.83 — a potential gain of +85% from today's $8.54. That is -4% versus the projected 2033 average. Momentum favours further upside here.
Ocular Therapeutix, Inc.'s 2035 outlook centres on $16.70, within a $11.16 to $27.05 range. That is up +5% on the projected 2034 average. That marks a +96% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, OCUL could reach as high as $41.39, with a base case around $23.96 and support toward $14.90 — roughly +181% from $8.54. Momentum favours further upside here.
Expect OCUL to range from $28.27 to $97.92 through 2050. The $51.63 average target implies a +505% move from current prices. That is up +115% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in OCUL today (≈ 117.096019 OCUL) could be worth
$6,045.33
+$5,045.33 (+505%) by 2050 · US Dollar
Based on the average projected OCUL price of $51.63 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OCULwould be worth at today's price.
$1,000 invested in OCUL on May 27, 2025 (≈ 144.092218 OCUL) would be worth
$1,230.55
+$230.55 (+23.1%) today · 1.23× · US Dollar
Based on a OCUL entry price of $6.94 vs. today's $8.54.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.03 | $1,063.51 | +6.4% |
| 1 month ago | $9.52 | $897.06 | -10.3% |
| 3 months ago | $9.59 | $890.51 | -10.9% |
| 6 months ago | $12.15 | $702.88 | -29.7% |
| 1 year ago | $6.94 | $1,230.55 | +23.1% |
| All time (5.0y) ago | $14.92 | $572.39 | -42.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OCUL forecast.
Our base-case forecast reaches $17.00 around 2040.
Implied market cap at $17.00: $3.72B
The multi-year forecast shows a shift from neutral in 2026 to a bullish trajectory from 2030 onward. In 2030, the average price is projected to be $12.27 with a min of $8.89 and a max of $18.30, yielding a 49 ROI and a bullish sentiment. By 2040, the average is $23.34 with a max of $40.86 and an ROI of 183.6, reinforcing a strong bullish outlook.
By 2050, the forecast envisions an average price of $51.34 and a max of $98.90, representing an ROI of 523.8 and a continuing bullish sentiment. The progression includes substantial year-by-year gains from 2031 through 2035 and beyond, reflecting an elongated uptrend in the model’s projection. These figures are estimates and not guarantees, and they depend on a range of market and company-specific factors.
Tap a question to reveal the answer.
In 2030 the forecast shows an average price of $12.27 with a min of $8.89 and a max of $18.30, and a ROI of 49. The sentiment is BULLISH.
The forecast turns bullish from 2030 onward, with 2030–2035 showing rising averages and higher eventual levels (2030 avg $12.27; 2040 avg $23.34; 2050 avg $51.34). The 2026 forecast is neutral, indicating a mixed near-term view. These are estimates, not guarantees, and depend on market and company factors.
The forecast max in 2050 is $98.90, which is below $100.
The current price is $8.23 and the market cap is $1.8B.
For 2026, the min is $6.88, the average is $8.23, and the max is $10.90, with an ROI of 0 and sentiment neutral.
Ocular Therapeutix, Inc. Community Discussion
0Share your Ocular Therapeutix, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.